Coinfection

HIV-positive people coinfected with hepatitis B virus (HBV) who were treated with 2 dually-active drugs -- one of them being tenofovir -- responded about as well as people taking only lamivudine or emtricitabine at 24 weeks, but over the longer term those on tenofovir plus either lamivudine or emtricitabine were more likely to maintain undetectable HBV viral load, according to a study published in a recent edition of AIDS.

HIV-positive people with hepatitis B virus (HBV) coinfection maintained HIV viral suppression, maintained or achieved HBV suppression, and showed improvements in kidney and bone markers when they switched to a single-tablet regimen containing the integrase inhibitor elvitegravir and a new safer formulation of tenofovir, according to a late-breaking poster presented at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention last month in Vancouver.

HIVandHepatitis.com coverage of the 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2014) in Boston, November 7-11, 2014.

Conference highlights include new interferon-free therapy for hepatitis C -- including options for people with cirrhosis, and liver transplant recipients -- treatment for hepatitis B, and prevention and management of advanced liver disease.

HIVandHepatitis.com coverage of the 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2014) in Boston, November 7-11, 2014.

Conference highlights include new interferon-free therapy for hepatitis C -- including options for people with cirrhosis, and liver transplant recipients -- treatment for hepatitis B, and prevention and management of advanced liver disease.

The 2015 Conference on Retroviruses and Opportunistic Infections (CROI) takes place this week, February 23-26, at the Washington State Convention Center in Seattle. CROI focuses on HIV treatment, prevention, and basic science. For the past several years it has also included substantial hepatitis C content, and this year will feature presentations on Ebola virus. HIVandHepatitis.com is on site in Seattle all week bringing you news coverage and Twitter updates (@HIVandHepatitis).

People with HIV/HBV coinfection being treated for both diseases had a significantly higher risk of hip fractures than patients with HIV alone or neither virus, according to research presented at IDWeek 2014 last week in Philadelphia.

The 2015 Conference on Retroviruses and Opportunistic Infections (CROI) takes place next week, February 23-26, at the Washington State Convention Center in Seattle. CROI focuses on HIV treatment, prevention, and basic science. For the past several years it has also included substantial hepatitis C content, and this year will feature presentations on Ebola virus. HIVandHepatitis.com will be on site in Seattle all week bringing you news coverage and Twitter updates (@HIVandHepatitis).

Tenofovir led to undetectable hepatitis B virus (HBV) levels in 87% of HIV positive coinfected individuals, and a similar proportion maintained viral suppression over 6 years, according to a study described in the June 20 advance edition of Hepatology.